|
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Contract/Alliance
Collaboration will develop and market Satellite Hot Labs for radiolabeling of BioGuides Berlin, Germany – 13 September 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreement with RefleXion Medical, Inc. (RefleXion) and Telix Pharmaceuticals Limited (ASX:TLX, Telix) to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling, quality control and storage of molecular targeting radiotracers, referred to as BioGuides, that are used in biology-guided radiotherapy (BgRT) to direct the radiation beam to indicated solid tumor cancers. The development of the SHL will allow radiolabeling of cold kits including Gallium-68 PSMA-11 (gallium-68 gozetotide, Illuccix®) for use with RefleXion’s BgRT technology (SCINTIX® therapy). Ga-68 PSMA-11 is currently approved in nuclear medicine for the diagnosis of late-stage prostate cancer and for selection of patients for Lutetium-177 PSMA therapy. The establishment of SHLs supports greater access for Ga-68 PSMA-11 to be used in the field of external-beam radiotherapy, that will offer a new treatment option for all prostate cancer stages. SHLs will enable greater flexibility for provision of radiotracers on-demand and in the shortest spatial distance to the linear accelerator, thus saving crucial resources. “We are excited to be part of this unique project, which will transfer and expand the use of Gallium-68 into radiation therapy,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler AG. “In addition to providing our extensive technological and regulatory expertise in the areas of radiosynthesis and quality control, this engagement offers great potential for our product GalliaPharm®.” "This agreement strengthens Telix’s collaborations with Eckert & Ziegler and RefleXion, two companies with whom we have built very strong working relationships. The combination of Illuccix with RefleXion’s innovative SCINTIX therapeutic technology is another example of the potential for Gallium-68-based PSMA imaging technology to enhance the management and treatment of prostate cancer,” said Richard Valeix, Group Chief Commercial Officer of Telix. "Our goal is to expand the patient population that can benefit from SCINTIX therapy to patients with prostate cancer through bringing Illuccix to market as a new BioGuide for SCINTIX,” said Thorsten Melcher, Ph.D., Chief Business Officer at RefleXion. “We are pleased to have two experienced partners at our side to jointly lead the SHL project to success.” About SCINTIX About GalliaPharm About Illuccix
Illuccix has been approved by the FDA, by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. Telix is also progressing Marketing Authorisation Applications for 68Ga-PSMA-11 in the United Kingdom and the European Union. About Eckert & Ziegler About Telix Pharmaceuticals Limited About RefleXion Medical Contact Telix Pharmaceuticals Limited RefleXion Medical, Inc.
13.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | karolin.riehle@ezag.de |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1723563 |
| End of News | EQS News Service |
|
|
1723563 13.09.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
